(Q54376487)
Statements
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer (English)
Johann S de Bono
Hardev S Pandha
Daniel P Petrylak
Luis Miguel A Aparicio
Peter Fong
Gary R Hudes
Tao Wang
Judith Scranton